PDF(Pubmed)
Abstract：
UNASSIGNED: Gastric residual volume (GRV) is considered an important parameter for gastric emptying and nutrition tolerance. This volume is measured before any nutrition and has a direct effect on the volume and timing of the next nutrition. The present study aimed to examine the GRV via ultrasound after receiving intravenous ondansetron, metoclopramide, and neostigmine.
UNASSIGNED: In the present study, 40 patients were included in the study, 10 patients were excluded from the study due to death during treatment, and 30 patients were divided into three groups of 10(10 patients in each group).The first, second, and third groups received 2.5, 10, and 8 mg neostigmine, metoclopramide, and ondansetron every 8 h, respectively. The drugs were infused as a micro set in 100 ml normal saline into patients within 30 min. The patients underwent ultrasound imaging and GRV measurement by an intensive care unit (ICU) subspecialty fellow, who was not aware of the drugs received by the patients, in the 1st h of hospitalization, 6 h after drug injection, and once daily for 4 days.
UNASSIGNED: A total of 40 patients entered the study based on inclusion and exclusion criteria. The effect of neostigmine on reducing GRV (Gastric residual volume) in ICU patients was better than those of the other two drugs, which was significant.
UNASSIGNED: The results of this study showed that neostigmine has a better and significant effect on reducing GRV in ICU patients, compared to those of ondansetron and metoclopramide.
UNASSIGNED: In the present study, 40 patients were included in the study, 10 patients were excluded from the study due to death during treatment, and 30 patients were divided into three groups of 10(10 patients in each group).The first, second, and third groups received 2.5, 10, and 8 mg neostigmine, metoclopramide, and ondansetron every 8 h, respectively. The drugs were infused as a micro set in 100 ml normal saline into patients within 30 min. The patients underwent ultrasound imaging and GRV measurement by an intensive care unit (ICU) subspecialty fellow, who was not aware of the drugs received by the patients, in the 1st h of hospitalization, 6 h after drug injection, and once daily for 4 days.
UNASSIGNED: A total of 40 patients entered the study based on inclusion and exclusion criteria. The effect of neostigmine on reducing GRV (Gastric residual volume) in ICU patients was better than those of the other two drugs, which was significant.
UNASSIGNED: The results of this study showed that neostigmine has a better and significant effect on reducing GRV in ICU patients, compared to those of ondansetron and metoclopramide.
摘要：
UNASSIGNED：胃残留量（GRV）被认为是胃排空和营养耐受性的重要参数。该体积是在任何营养之前测量的，并且对下一次营养的体积和时间有直接影响。本研究旨在通过接受静脉注射昂丹司琼的超声检查GRV，甲氧氯普胺,和新斯的明.
未经批准：在本研究中，40名患者被纳入研究，10名患者因治疗期间死亡而被排除在研究之外，将30例患者分为三组，每组10例（每组10例）。第一,第二,第三组接受2.5、10和8毫克新斯的明，甲氧氯普胺,和昂丹司琼每8小时，分别。在30分钟内将药物以100ml生理盐水中的微量输注给患者。患者接受了重症监护病房（ICU）亚专科研究员的超声成像和GRV测量，谁不知道病人接受的药物，在住院的第一个h，药物注射后6小时，每天一次，持续4天。
UNASSIGNED：共有40名患者根据纳入和排除标准进入研究。新斯的明降低ICU患者GRV(胃残留量)的效果优于其他两种药物,这很重要。
UNASSIGNED：这项研究的结果表明，新斯的明对降低ICU患者的GRV具有更好且显着的作用，与昂丹司琼和甲氧氯普胺相比。
未经批准：在本研究中，40名患者被纳入研究，10名患者因治疗期间死亡而被排除在研究之外，将30例患者分为三组，每组10例（每组10例）。第一,第二,第三组接受2.5、10和8毫克新斯的明，甲氧氯普胺,和昂丹司琼每8小时，分别。在30分钟内将药物以100ml生理盐水中的微量输注给患者。患者接受了重症监护病房（ICU）亚专科研究员的超声成像和GRV测量，谁不知道病人接受的药物，在住院的第一个h，药物注射后6小时，每天一次，持续4天。
UNASSIGNED：共有40名患者根据纳入和排除标准进入研究。新斯的明降低ICU患者GRV(胃残留量)的效果优于其他两种药物,这很重要。
UNASSIGNED：这项研究的结果表明，新斯的明对降低ICU患者的GRV具有更好且显着的作用，与昂丹司琼和甲氧氯普胺相比。
